There appears to be a risk for type 2 diabetes for people who take finasteride in the treatment of Benign Prostate Enlargement

https://www.bmj.com/content/365/bmj.l1204

Conclusions The risk of developing new onset type 2 diabetes appears to be higher in men with benign prostatic hyperplasia exposed to 5?-reductase inhibitors than in men receiving tamsulosin, but did not differ between men receiving dutasteride and those receiving finasteride. Additional monitoring might be required for men starting these drugs, particularly in those with other risk factors for type 2 diabetes.